EAST FALMOUTH, Mass., June 3 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a leading manufacturer of endotoxin and beta-glucan detection products, today announced that the Fungitell(R) assay kit, for the measurement of (1-->3)-beta-D-Glucan, a fungal cell wall component, has been CE marked, which enables distribution in the European Union (EU). In addition, this important assay has been included in both the Infectious Disease Society of America's (IDSA) Clinical Practice Guidelines for the treatment of Aspergillosis, and the National Comprehensive Cancer Network(R) (NCCN) 2008 Clinical Practice Guidelines in Oncology(TM), "Prevention and Treatment of Cancer-Related Infections." The IDSA guidelines are published in the February 1st edition of the Clinical Infectious Diseases 2008; 46:327-60, and can be viewed at http://www.journals.uchicago.edu/toc/cid/46/3. The NCCN guideline was published 1/16/08, and can be viewed at http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf. The revised European Organization for Research and Treatment of Cancer-Mycosis Study Group (EORTC-MSG) definitions will be appearing in the June 15, 2008 edition of Clinical Infections Diseases (Univ. of Chicago Press).
Fungitell(R) measures (1-->3)-beta-D-Glucan in patient serum and is sensitive to as little as a few trillionths of a gram. The assay is used for patients at risk of fungal infection, including immuno-compromised patients, such as transplant recipients or those with cancer. The kit can be used in hospital laboratories or patient samples can be tested at ACC's Beacon Diagnostics(R) Laboratory.
Dr. AJ Meuse, President and CEO of ACC, stated, "The CE mark opens the
door for distribution in all EU member states. Since the introduction of
Fungitell(R), we have had numerous inquiries
|SOURCE Associates of Cape Cod, Inc.|
Copyright©2008 PR Newswire.
All rights reserved